Manuscript title Prospective evaluation of oral levetiracetam for
prophylaxis of busulfan-induced seizures in children undergoing
hematopoietic stem cell transplantation
- Marcelo de Melo Aragão,
- Gustavo Zamperlini,
- Adriana Seber
, - Zecchin VG,
- Cintia Monteiro Lustosa,
- Ricardo Pinho,
- Marcelo Rodrigues
Marcelo de Melo Aragão
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Corresponding Author:aragao@unifesp.br
Author ProfileGustavo Zamperlini
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author ProfileAdriana Seber

Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author ProfileCintia Monteiro Lustosa
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author ProfileRicardo Pinho
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author ProfileMarcelo Rodrigues
Instituto de Neurociência do Espírito Santo
Author ProfileAbstract
Busulfan is commonly used in the conditioning regimen for hematopoietic
stem cell transplantation. Due to the risk of seizures associated with
its use, prophylaxis with an anti-seizure drug is required. We
prospectively evaluated the effectiveness of oral levetiracetam in
children and adolescents for the prevention of busulfan-induced
seizures. None of the 64 patients included in the study experienced
seizures during the conditioning therapy or side effects that required
discontinuation of the drug. Our results suggest that oral levetiracetam
is effective in this setting.24 May 2023Assigned to Editor 24 May 2023Submission Checks Completed
24 May 2023Submitted to Pediatric Blood & Cancer 24 May 2023Review(s) Completed, Editorial Evaluation Pending
25 May 2023Reviewer(s) Assigned